U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H20N4O
Molecular Weight 308.3776
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DERENOFYLLINE

SMILES

O[C@H]1CC[C@@H](CC1)NC2=C3C=CNC3=NC(=N2)C4=CC=CC=C4

InChI

InChIKey=RBZNJGHIKXAKQE-HDJSIYSDSA-N
InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)/t13-,14-

HIDE SMILES / InChI

Molecular Formula C18H20N4O
Molecular Weight 308.3776
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800016704 | https://www.ncbi.nlm.nih.gov/pubmed/17558436 |

Derenofyllin (SLV320) is a selective adenosine A1 receptor antagonist, which is under investigation for the treatment of heart failure with renal dysfunction. Adverse events considered related to SLV320 were dizziness, nausea, transient hypertension and transient hypotension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.13 h
15 mg single, intravenous
dose: 15 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DERENOFYLLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 2 times / day multiple, intravenous
Highest studied dose
Dose: 15 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 15 mg, 2 times / day
Sources: Page: p.1016
unhealthy, ADULT
n = 9
Health Status: unhealthy
Condition: heart disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 9
Sources: Page: p.1016
15 mg single, intravenous
Highest studied dose
Dose: 15 mg
Route: intravenous
Route: single
Dose: 15 mg
Sources: Page: p.527
unhealthy, ADULT
n = 22
Health Status: unhealthy
Condition: heart disease
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 22
Sources: Page: p.527
PubMed

PubMed

TitleDatePubMed
The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.
2007 Aug
A1 adenosine receptor antagonists, agonists, and allosteric enhancers.
2009
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
2009 Nov
Patents

Sample Use Guides

1-hour infusion of 5, 10, and 15 mg SLV320
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:11:49 GMT 2023
Edited
by admin
on Fri Dec 15 17:11:49 GMT 2023
Record UNII
O1Q96UZ63W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DERENOFYLLINE
INN  
INN  
Official Name English
SLV-320
Code English
CYCLOHEXANOL, 4-((2-PHENYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)-, TRANS-
Systematic Name English
TRANS-4-((2-PHENYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOHEXANOL
Systematic Name English
derenofylline [INN]
Common Name English
SLV320
Code English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
Code System Code Type Description
FDA UNII
O1Q96UZ63W
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
NCI_THESAURUS
C96199
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID30948047
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
SMS_ID
100000175027
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
INN
9208
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL592435
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
CAS
251945-92-3
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
DRUG BANK
DB12446
Created by admin on Fri Dec 15 17:11:49 GMT 2023 , Edited by admin on Fri Dec 15 17:11:49 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY